Simulations Plus, Inc. (SLP) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Health Information Services) last closed at $18.36. The rating moved from Neutral to Overbought on August 14, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$18.36
• Last changeMoved from Neutral to Overbought on August 14, 2026
• SectorHealthcare
• IndustryHealth Information Services

See all overbought Healthcare stocks →

AI analysis

Simulations Plus, Inc. benefits from a focused product suite for ADMET and PK/PD simulation with recurring revenue characteristics and meaningful readthrough from growing biologics and CRO demand. Adoption of AI/ML in drug development represents a tangible growth vector that can expand license uptake and high-margin services. Near-term performance will be sensitive to deal timing, R&D budgets at pharma clients, and broader small-cap sentiment. Competitive dynamics and client concentration remain the main execution risks. Overall financial health appears acceptable for a specialized software/services firm, but investors should monitor contract cadence, product commercialization of AI initiatives, and cash-flow generation over the next several quarters.

Key factors

• Niche leadership in in silico ADMET and pharmacokinetic/pharmacodynamic modeling with sticky software and service relationships
• Recurring-license and services revenue mix that can provide revenue visibility and margin leverage as adoption grows
• Readthrough from increased biologics, oncology and CRO/CDMO spend that expands addressable market for modeling and simulation tools
• Growing interest in AI/ML-driven drug discovery and development which can enhance product demand and pricing power
• Strong client base among pharma and biotech which supports cross-sell opportunities and multi-year engagements
• Relatively low correlation to cyclical end-markets compared with pure biotech, giving defensive qualities in mixed market environments

Risks

• Concentration risk from a limited number of large clients or contracts that can materially affect revenue if lost or delayed
• Intense competition from larger modeling/simulation and computational chemistry firms, and open-source/academic tools
• R&D and clinical spending variability at pharma/biotech customers that can delay purchases or reduce services demand
• Execution risk ramping new AI-driven products and integrating them into customer workflows
• Small-cap liquidity and valuation volatility which can amplify share-price moves on limited news
• Regulatory or data-privacy developments that could increase compliance costs or constrain certain data-driven services

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.